JP2011500713A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500713A5
JP2011500713A5 JP2010530110A JP2010530110A JP2011500713A5 JP 2011500713 A5 JP2011500713 A5 JP 2011500713A5 JP 2010530110 A JP2010530110 A JP 2010530110A JP 2010530110 A JP2010530110 A JP 2010530110A JP 2011500713 A5 JP2011500713 A5 JP 2011500713A5
Authority
JP
Japan
Prior art keywords
cancer
compound
pharmaceutically acceptable
acceptable salt
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010530110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500713A (ja
JP5496899B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/080163 external-priority patent/WO2009052287A1/en
Publication of JP2011500713A publication Critical patent/JP2011500713A/ja
Publication of JP2011500713A5 publication Critical patent/JP2011500713A5/ja
Application granted granted Critical
Publication of JP5496899B2 publication Critical patent/JP5496899B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010530110A 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン Active JP5496899B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
US60/980,397 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014043175A Division JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン

Publications (3)

Publication Number Publication Date
JP2011500713A JP2011500713A (ja) 2011-01-06
JP2011500713A5 true JP2011500713A5 (US20070167479A1-20070719-C00034.png) 2011-12-01
JP5496899B2 JP5496899B2 (ja) 2014-05-21

Family

ID=40251685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010530110A Active JP5496899B2 (ja) 2007-10-16 2008-10-16 シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014043175A Active JP5859588B2 (ja) 2007-10-16 2014-03-05 シチジンデアミナーゼ阻害剤としての2’−フルオロ−2’−デオキシテトラヒドロウリジン

Country Status (39)

Country Link
US (4) US8268800B2 (US20070167479A1-20070719-C00034.png)
EP (2) EP2447272B1 (US20070167479A1-20070719-C00034.png)
JP (2) JP5496899B2 (US20070167479A1-20070719-C00034.png)
KR (1) KR101543049B1 (US20070167479A1-20070719-C00034.png)
CN (1) CN101827856B (US20070167479A1-20070719-C00034.png)
AT (1) ATE548374T1 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0818672B8 (US20070167479A1-20070719-C00034.png)
CA (1) CA2702274C (US20070167479A1-20070719-C00034.png)
CO (1) CO6270330A2 (US20070167479A1-20070719-C00034.png)
CR (1) CR11427A (US20070167479A1-20070719-C00034.png)
CY (3) CY1112781T1 (US20070167479A1-20070719-C00034.png)
DK (1) DK2207786T3 (US20070167479A1-20070719-C00034.png)
EA (1) EA018757B1 (US20070167479A1-20070719-C00034.png)
EC (1) ECSP10010095A (US20070167479A1-20070719-C00034.png)
ES (2) ES2384011T3 (US20070167479A1-20070719-C00034.png)
FI (2) FIC20230040I1 (US20070167479A1-20070719-C00034.png)
FR (2) FR23C1051I1 (US20070167479A1-20070719-C00034.png)
GT (1) GT201000088A (US20070167479A1-20070719-C00034.png)
HK (1) HK1146410A1 (US20070167479A1-20070719-C00034.png)
HR (1) HRP20120419T1 (US20070167479A1-20070719-C00034.png)
HU (2) HUS2300044I1 (US20070167479A1-20070719-C00034.png)
IL (1) IL204732A (US20070167479A1-20070719-C00034.png)
JO (1) JO2778B1 (US20070167479A1-20070719-C00034.png)
ME (1) ME00997B (US20070167479A1-20070719-C00034.png)
MX (1) MX2010004109A (US20070167479A1-20070719-C00034.png)
MY (1) MY147970A (US20070167479A1-20070719-C00034.png)
NI (1) NI201000055A (US20070167479A1-20070719-C00034.png)
NL (1) NL301256I2 (US20070167479A1-20070719-C00034.png)
NO (2) NO2023048I1 (US20070167479A1-20070719-C00034.png)
NZ (1) NZ584229A (US20070167479A1-20070719-C00034.png)
PL (1) PL2207786T3 (US20070167479A1-20070719-C00034.png)
PT (1) PT2207786E (US20070167479A1-20070719-C00034.png)
RS (1) RS52323B (US20070167479A1-20070719-C00034.png)
SA (1) SA08290661B1 (US20070167479A1-20070719-C00034.png)
SI (1) SI2207786T1 (US20070167479A1-20070719-C00034.png)
TW (1) TWI445539B (US20070167479A1-20070719-C00034.png)
UA (1) UA99476C2 (US20070167479A1-20070719-C00034.png)
WO (1) WO2009052287A1 (US20070167479A1-20070719-C00034.png)
ZA (1) ZA201002178B (US20070167479A1-20070719-C00034.png)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
ES2969144T3 (es) 2008-05-15 2024-05-16 Celgene Corp Formulaciones orales de análogos de citidina y métodos de uso de los mismos
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
CL2009002206A1 (es) * 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
WO2010118013A1 (en) * 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
AR084044A1 (es) 2010-11-30 2013-04-17 Pharmasset Inc Compuestos 2’-espiro-nucleosidos
CN104244945B (zh) 2011-09-16 2016-08-31 吉利德制药有限责任公司 用于治疗hcv的方法
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
DK2950786T3 (da) 2013-01-31 2020-02-17 Gilead Pharmasset Llc Kombinationsformulering af to antivirale forbindelser
ES2792503T3 (es) 2013-08-27 2020-11-11 Gilead Pharmasset Llc Formulación combinada de dos compuestos antivirales
CA2926734C (en) * 2013-10-29 2022-03-15 Otsuka Pharmaceutical Co., Ltd. Synthetic route to 2'-deoxy-2',2'-difluorotetrahydrouridines
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
WO2017096357A1 (en) 2015-12-03 2017-06-08 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
WO2019152955A1 (en) 2018-02-02 2019-08-08 Steven Albert Everett Small molecule drug conjugates of gemcitabine monophosphate
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
US20210388361A1 (en) * 2018-10-19 2021-12-16 Interoligo Corporation Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
CN112888700A (zh) * 2018-10-19 2021-06-01 因特欧力多公司 具有改善治疗功效的修饰核酸和含有其的抗癌药物组合物
MX2022004271A (es) * 2019-10-08 2022-06-09 Otsuka Pharma Co Ltd 2'-desoxi-2',2'-difluoro tetrahidruridina de alta pureza y metodos para su preparacion.
EP4069254A4 (en) * 2020-02-25 2023-11-29 Otsuka Pharmaceutical Co., Ltd. ORAL SOLID DOSAGE FORMS OF DEITABINE AND CEDURIDINE
BR112023019182A2 (pt) * 2021-03-26 2023-11-28 Cleveland Clinic Found Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
US11938143B2 (en) 2021-10-19 2024-03-26 Akirabio, Inc. Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0160079B1 (en) 1983-10-26 1990-01-31 GREER, Sheldon B. Method and materials for sensitizing neoplastic tissue to radiation
IL77133A (en) 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
WO1992018617A1 (en) 1991-04-23 1992-10-29 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
AU664948B2 (en) 1993-02-23 1995-12-07 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
AU6081294A (en) * 1993-05-14 1994-12-12 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
DK1156827T3 (da) * 1999-03-01 2007-02-05 Halogenetics Inc Anvendelse af sammensætninger omfattende CldC som strålingssensibilisatorer ved behandlingen af neoplastiske sygdomme
WO2001013789A1 (en) 1999-08-26 2001-03-01 Aortech International Plc Improvements relating to catheter positioning
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
EP1348712B1 (en) 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Processes and intermediates in the synthesis of L-thymidine
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
AU2002257446A1 (en) 2001-05-18 2002-12-03 Rakesh Kumar Antiviral nucleosides
US8207142B2 (en) * 2001-07-31 2012-06-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibitor of DNA methylation
JP2005522443A (ja) 2002-02-14 2005-07-28 フアーマセツト・リミテツド 改変フッ素化ヌクレオシド類似体
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
EP1545558A4 (en) 2002-09-24 2010-02-17 Koronis Pharmaceuticals Inc 1, 3, 5-TRIAZINES FOR THE TREATMENT OF VIRAL DISEASES
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
WO2006015346A1 (en) 2004-07-30 2006-02-09 Pharmaessentia Corp. STEREOSELECTIVE SYNTHESIS OF β-NUCLEOSIDES
WO2006063105A1 (en) 2004-12-08 2006-06-15 Sicor Inc. Difluoronucleosides and process for preparation thereof
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
WO2010118013A1 (en) 2009-04-06 2010-10-14 Eisai Inc. Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
TWI477508B (zh) 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Similar Documents

Publication Publication Date Title
JP2011500713A5 (US20070167479A1-20070719-C00034.png)
HRP20120419T1 (hr) Fluoro deoksitetrahidrouridini kao inhibitori citidin deaminaze
JP2012522842A5 (US20070167479A1-20070719-C00034.png)
JP2014177455A5 (US20070167479A1-20070719-C00034.png)
JP2008536853A5 (US20070167479A1-20070719-C00034.png)
JP2009502743A5 (US20070167479A1-20070719-C00034.png)
JP2017511311A5 (US20070167479A1-20070719-C00034.png)
JP2008528671A5 (US20070167479A1-20070719-C00034.png)
JP2013518107A5 (US20070167479A1-20070719-C00034.png)
JP2011501962A5 (US20070167479A1-20070719-C00034.png)
JP2015508103A5 (US20070167479A1-20070719-C00034.png)
JP2014193925A5 (US20070167479A1-20070719-C00034.png)
JP2010504079A5 (US20070167479A1-20070719-C00034.png)
JP2010523670A5 (US20070167479A1-20070719-C00034.png)
JP2009515980A5 (US20070167479A1-20070719-C00034.png)
JP2009543802A5 (US20070167479A1-20070719-C00034.png)
JP2006507308A5 (US20070167479A1-20070719-C00034.png)
JP2008528701A5 (US20070167479A1-20070719-C00034.png)
JP2009536191A5 (US20070167479A1-20070719-C00034.png)
JP2010540556A5 (US20070167479A1-20070719-C00034.png)
JP2015500885A5 (US20070167479A1-20070719-C00034.png)
JP2009503110A5 (US20070167479A1-20070719-C00034.png)
JP2012522841A5 (US20070167479A1-20070719-C00034.png)
JP2011509956A5 (US20070167479A1-20070719-C00034.png)
JP2017526662A5 (US20070167479A1-20070719-C00034.png)